Pharma BD Deal Intelligence
Voyager Therapeutics entered a capsid license agreement and strategic collaboration with Novartis (announced January 2, 2024) to advance AAV gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA) using Voyager's TRACER capsid platform. Voyager received $100M upfront ($80M cash plus a $20M equity investment in newly issued shares) and is eligible for up to $1.2B in preclinical, development, regulatory and sales milestones, plus tiered royalties on TRACER-enabled products (total potential value ~$1.3B). Novartis takes worldwide rights to the HD gene therapy (Voyager leads preclinical; Novartis leads clinical development and commercialization) and target-exclusive TRACER access for the SMA program, which Novartis develops and commercializes.